HomeIMC • ASX
add
Immuron Ltd
Previous close
$0.076
Day range
$0.077 - $0.077
Year range
$0.065 - $0.17
Market cap
16.32M AUD
Avg Volume
129.80K
P/E ratio
-
Dividend yield
-
Primary exchange
ASX
Market news
Financials
Income Statement
Revenue
Net income
| (AUD) | Jun 2024info | Y/Y change |
|---|---|---|
Revenue | 1.27M | 108.61% |
Operating expense | 2.56M | 79.40% |
Net income | -2.43M | -169.00% |
Net profit margin | -190.94 | -28.94% |
Earnings per share | — | — |
EBITDA | -1.68M | -118.52% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (AUD) | Jun 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 11.66M | -32.07% |
Total assets | 15.55M | -29.28% |
Total liabilities | 2.84M | 19.79% |
Total equity | 12.71M | — |
Shares outstanding | 228.00M | — |
Price to book | 1.27 | — |
Return on assets | -27.02% | — |
Return on capital | -32.61% | — |
Cash Flow
Net change in cash
| (AUD) | Jun 2024info | Y/Y change |
|---|---|---|
Net income | -2.43M | -169.00% |
Cash from operations | -1.94M | -141.79% |
Cash from investing | 87.03K | 1,082.80% |
Cash from financing | 12.00K | 203.57% |
Net change in cash | -1.78M | -170.36% |
Free cash flow | -1.03M | -197.20% |
About
Immuron is a biotechnology company based in Melbourne, Australia. In 2008, the company changed its name to Immuron Limited, having previously operated as Anadis Limited.
Immuron is focused on antigen-primed and dairy-derived health products. Its proprietary technologies allow for rapid development of polyclonal antibody and other proteins-based solutions for a range of diseases. The company specialises in nutraceutical, pharmaceutical and therapeutic technology products for conditions such as oral and GI mucositis, avian influenza, E. coli travellers' diarrhoea and Anthrax containment.
In 2005, Anadis signed an agreement with Quebec's Baralex Inc. and Valeo Pharma Inc. for the distribution of Travelan, a product made by Anadis for the Canadian market. Wikipedia
Founded
1994
Headquarters
Website
Employees
7
